Acton-based Bluejay Diagnostics, Inc. has partnered with Tokyo-based Toray Industries to develop a minimally-invasive, point-of-care test for COVID-19 patients to assess progression of the disease.
The test, Symphony IL-6, measures the quantity of white blood cell protein in whole blood. It can be used with COVID-19 patients who present progressing symptoms as an aid in predicting the patients risk for intubation, according to a release from Bluejay, which manufactures and markets innovative clinical diagnostic products..
“Through our collaboration with Toray, we hope to deliver rapid, point-of-care tests that enhance patient care and save lives,” Neil Dey, CEO of Bluejay, said in the release.
Under the agreement, Toray will license its technology to Bluejay, which expects to perform clinical trials through an emergency use authorization in the United States.
Financial arrangements of the agreement were not disclosed.
